Efficacy of Coenzyme q10 in Pediatrics With Type 1 Diabetes Mellitus

Effect of Coenzyme Q10 on Markers of Endothelial Dysfunction in Pediatric Patients With Type 1 Diabetes Mellitus

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03111433

Enrollment

Registered

2017-04-12

Start date

2017-03-19

Completion date

2018-01-20

Last updated

2018-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Keywords

Type 1 Diabetes mellitus, Coenzyme Q10, endothelial dysfunction, pediatric patients

Brief summary

The purpose of this study is to determine wether coenzyme Q10 is effective in reducing markers of endothelial dysfunction in pediatric patients with type 1 diabetes mellitus and aslo to investigate its effect on glycemic control and lipid profile of those patients and its effect on patient's quality of life.

Interventions

DIETARY_SUPPLEMENTCoenzyme Q10

Coenzyme Q10 soft gelatin capsule 100mg

DRUGInsulin

multiple dose insulin injection therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

8 Years to 18 Years

Healthy volunteers

Inclusion criteria

1. Age: patients from 8 to 18 years old. 2. Outpatient with at least 1 year history of type 1 diabetes mellitus. 3. Insulin requirement of more than or equal 0.5 U/Kg/day. 4. Approval to participate and give informed consent.

Exclusion criteria

1. Presence of systemic disorders such as celiac disease, hypothyroidism or hyperthyroidism. 2. Preexisting cardiovascular disease or hypertension. 3. Chronic kidney disease or chronic liver disease. 4. Significant mental illness. 5. Intake of other antioxidants such as ascorbic acid and α-tocopherol and omega3 supplement within the last 3 months. 6. Intake of coenzyme Q10 within the last 3 months.

Design outcomes

Primary

Measure	Time frame	Description
change in soluble interacellular adhesion molecule level	three months	it will be assessed at baseline and after three months of treatment

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026